Moreover, our findings demonstrate that anti-IL-9 antibodies markedly suppress tumor growth in vivo and identify IL-9R+ TILs and lung adenocarcinoma cells as targets for IL-9 signaling. The gene discussed is IL9; the disease is neoplasm.